AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
202.72
-0.05 (-0.02%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close202.77
Open203.17
Bid0.00 x 800
Ask0.00 x 800
Day's Range200.28 - 204.51
52 Week Range163.31 - 210.19
Volume1,898,677
Avg. Volume2,515,889
Market Cap131.215B
Beta (3Y Monthly)1.53
PE Ratio (TTM)60.73
EPS (TTM)3.34
Earnings DateOct 30, 2018
Forward Dividend & Yield5.28 (2.60%)
Ex-Dividend Date2018-08-16
1y Target Est205.15
Trade prices are not sourced from all markets
  • Novartis Missed Revenue Estimates in Q3 2018
    Market Realist13 hours ago

    Novartis Missed Revenue Estimates in Q3 2018

    Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.

  • PR Newswire18 hours ago

    Amgen Invests £50 Million ($66 Million) In Oxford Nanopore Technologies

    THOUSAND OAKS, Calif. and OXFORD, England, Oct. 18, 2018 /PRNewswire/ -- Amgen (AMGN) and Oxford Nanopore Technologies Ltd. today announced Amgen's equity investment of £50 million ($66 million) in Oxford Nanopore, a privately-owned, UK-based company advancing a new generation of portable, real-time genetic sequencing technology. Oxford Nanopore has developed and brought to market a proprietary sequencing technology that uses many nanopores (nano-scale holes made by proteins contained within a synthetic membrane) in combination with electronics to perform direct, real-time sequencing of DNA and RNA. The investment in Oxford Nanopore aligns with Amgen's strategic focus on using human genetics to deliver new medicines to patients.

  • Amgen Launches Humira Biosimilar in Europe
    GuruFocus.comyesterday

    Amgen Launches Humira Biosimilar in Europe

    Amgen (AMGN) soared 3.45% to $202.34 per share on Oct. 16 following the commercial launch of Amgevita in Europe. Amgevita is a biosimilar of AbbVie's (ABBV) Humira and the trade name of adalimumab. The product is used as a treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, chronic psoriasis and other conditions.

  • Reuters2 days ago

    Exclusive: Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
    Reuters2 days ago

    Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva

    Express Scripts Holding Co, one of the largest U.S. prescription benefits managers, will cover new migraine drugs from Eli Lilly and Amgen Inc, but exclude a rival medication from Teva Pharmaceutical Industries Ltd after price negotiations with all three manufacturers. The decision represents a setback for Israel-based Teva , which is in the midst of a corporate restructuring and had hoped to capture a sizable share of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use of the Amgen and Lilly migraine drugs to patients it says are most likely to benefit from them.

  • Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises
    Investing.com2 days ago

    Stocks - Netflix Soars in Pre-market; IBM, Tilray, Canopy Growth Sink; Tesla Rises

    Investing.com - Stocks in focus in pre-market trade Wednesday:

  • Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?
    Zacks2 days ago

    Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?

    Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.

  • The Wall Street Journal2 days ago

    [$$] By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S.

    Cheaper copies of the world’s biggest-selling drug will roll out across Europe this week after a key European patent for Humira expires Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the blockbuster drug. The reason: a formidable wall of patents built up by Humira-maker AbbVie Inc., that prevents the developers of “biosimilar” versions launching their products in the U.S. Biosimilars are near-copies of biologic drugs, such as Humira, that are made from living cells in a process that resembles brewing.

  • Investing.com2 days ago

    Amgen Rises 3%

    Investing.com - Amgen (NASDAQ:AMGN) rose by 3.10% to trade at $201.66 by 14:31 (18:31 GMT) on Tuesday on the NASDAQ exchange.

  • How Nektar Therapeutics Is Positioned In October
    Market Realist2 days ago

    How Nektar Therapeutics Is Positioned In October

    Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.

  • 4 Strong Stocks to Buy That Double As Big Takeover Targets
    InvestorPlace3 days ago

    4 Strong Stocks to Buy That Double As Big Takeover Targets

    One of the quickest ways to make money in the stock market is through M&A. Acquisition premiums are usually in excess of 20%, so if you own stock in a company and that company gets acquired, you could easily make 20% or more in a day. The potential rewards from takeover stocks are compelling.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Enzo's Q4 Loss, Sanofi's Positive Trial Results, ImmunoCellular To Delist

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 15) BioDelivery Sciences International, Inc. (NASDAQ: BDSI ...

  • Reuters3 days ago

    Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU

    Rival versions of the world’s top-selling drug, AbbVie's Humira, went on sale in Europe on Tuesday, years ahead of similar cut-price copies being available in the United States. Amgen is rolling out its so-called biosimilar form of Humira, branded as Amgevita, across Europe from Oct. 16, while Novartis said its Sandoz unit was launching its product Hyrimoz initially in Britain, with other markets set to follow. Large sums are at stake, since Humira clocked up worldwide sales of $18 billion last year, of which around $4 billion came from Europe, and European healthcare administrators are eager to exploit the competitive situation to drive down drug bills.

  • PR Newswire3 days ago

    Amgen Launches AMGEVITA™ (Biosimilar Adalimumab) In Markets Across Europe

    THOUSAND OAKS, Calif., Oct. 15, 2018 /PRNewswire/ -- Amgen (AMGN) today announced that AMGEVITATM, a biosimilar to adalimumab, will launch in markets across Europe beginning on Oct. 16, 2018. AMGEVITA is the first adalimumab biosimilar to be approved by the European Commission (EC).

  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance3 days ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • Immune Design to Halt Cancer Vaccine Program, Shares Plunge
    Zacks4 days ago

    Immune Design to Halt Cancer Vaccine Program, Shares Plunge

    Immune Design (IMDZ) to discontinue the CMB305 cancer vaccine program and focus on the development of its lymphoma therapy, G100.

  • Top Ranked Income Stocks to Buy for October 15th
    Zacks4 days ago

    Top Ranked Income Stocks to Buy for October 15th

    Top Ranked Income Stocks to Buy for October 15th

  • AbbVie Settles With Novartis to Delay Humira Biosimilar in US
    Zacks7 days ago

    AbbVie Settles With Novartis to Delay Humira Biosimilar in US

    AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.

  • Reuters7 days ago

    Abbvie settles Humira patent disputes with Novartis unit

    Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira. Abbvie, however, did not disclose details regarding the royalties it will receive from Novartis generics unit, Sandoz, as part of the agreement. Shares of Abbvie rose 2.39 percent to $92.87 in after-market trading.

  • Here's Why Coherus BioSciences Fell 18.1% in September
    Motley Fool7 days ago

    Here's Why Coherus BioSciences Fell 18.1% in September

    Enthusiasm for the biopharma is wearing off despite its announcement of an important commercial milestone.

  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Fool8 days ago

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Healthcare Stocks in the Red amid Broader Market Sell-Off
    Market Realist8 days ago

    Healthcare Stocks in the Red amid Broader Market Sell-Off

    Yesterday, most healthcare stocks were trading below their previous day’s closing price. Biotech players seem to have been hit the worst. However, all other sectors including pharmaceuticals, medical devices, and hospitals saw significant weakness. Johnson & Johnson (JNJ), Boston Scientific (BSX), Pfizer (PFE), Merck (MRK), and Bristol-Myers Squibb fell 1.1%, 2.1%, 2.6%, and 3.9%, respectively, yesterday. Major biotechnology players Gilead Sciences (GILD), Amgen (AMGN), Biogen (BIIB), and Novo Nordisk (NVO) fell 2.30%, 2.33%, 2.04%, and 1.81%, respectively.

  • Celgene: Multiple Myeloma Franchise Could Drive Growth
    Market Realist9 days ago

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    How's Celgene Positioned before Its Third-Quarter Earnings? Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).

  • Tilary Buys Alef Biotechnology to Build Base in Latin America
    Zacks9 days ago

    Tilary Buys Alef Biotechnology to Build Base in Latin America

    Tilary (TLRY) acquires import and distribution partner, Alef Biotechnology to strengthen its base in Latin America.

  • Celgene: Analysts’ Views before Its Third-Quarter Earnings
    Market Realist9 days ago

    Celgene: Analysts’ Views before Its Third-Quarter Earnings

    Wall Street analysts expect Celgene to report a net income and EPS of $1.2 billion and $1.71, respectively, in the third quarter.